精确疫苗学方法用于开发针对特定弱势群体的辅助疫苗
Branden Lee1, Etsuro Nanishi1,2, Ofer Levy1,2,3
1Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA.
Pharmaceutics
|June 28, 2023
概括
精密疫苗学通过选择有效的辅助剂-抗原组合和配方系统来优化弱势群体的免疫接种. 这种方法提高了疫苗的有效性和安全性,以防范流行病.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 公共卫生 公共卫生
背景情况:
- 感染仍然是全球疾病和死亡的主要原因,不成比例地影响到非常年轻,老年人,免疫力低下者和患有慢性疾病的人.
- 了解脆弱人群中的免疫系统变异对于开发有效疫苗至关重要.
- 精密疫苗学旨在根据整个生命周期的特定需求量身定制免疫.
研究的目的:
- 探索精确疫苗学的关键要素,以防范流行病和大流行病.
- 确定优化疫苗成分的策略,包括辅助剂和抗原.
- 检查配方系统和注射途径,以改善疫苗的结果.
主要方法:
- 专注于选择强大的疫苗辅助剂和抗原组合.
- 合适的配方系统与疫苗平台的整合.
- 考虑免疫目标,如免疫性,传播减少和安全性.
主要成果:
- 精确疫苗学为开发有针对性的疫苗提供了一个框架.
- 优化辅助抗原选择和配方是疫苗成功的关键.
- 解决管理途径的挑战和减少不良反应至关重要.
结论:
- 精确疫苗学的持续创新正在扩大疫苗组件.
- 有针对性的疫苗策略对于保护弱势群体至关重要.
- 定制方法对于有效的流行病和流行病应对至关重要.
相关概念视频
Vaccinations
44.8K
Overview
44.8K
Cancer Vaccines
433
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
433
Microorganisms in Medicine and Therapeutics
68
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
68
Development of Immunocompetence
366
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
366


